Hindawi Publishing Corporation

Disease Markers
Volume 35 (2013), Issue 6, Pages 727–734
http://dx.doi.org/10.1155/2013/726598

Review Article
Rheumatoid Factors: Clinical Applications

Francesca Ingegnoli,1 Roberto Castelli,2 and Roberta Gualtierotti1

1
Division of Rheumatology, Istituto Gaetano Pini, Department of Clinical Science & Community Health,
University of Milan, 20122 Milan, Italy
2
Internal Medicine Section, IRCCS, Ca’ Granda Policlinico, Department of Pathophysiology and Transplation,
University of Milan, 20122 Milan, Italy

Correspondence should be addressed to Francesca Ingegnoli; [email protected]

Received 25 June 2013; Revised 10 September 2013; Accepted 1 October 2013

Academic Editor: Irene Rebelo

Copyright © 2013 Francesca Ingegnoli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.

Rheumatoid factors are antibodies directed against the Fc region of immunoglobulin G. First detected in patients with rheumatoid
arthritis 70 years ago, they can also be found in patients with other autoimmune and nonautoimmune conditions, as well as in
healthy subjects. Rheumatoid factors form part of the workup for the differential diagnosis of arthropathies. In clinical practice,
it is recommended to measure anti-cyclic citrullinated peptide antibodies and rheumatoid factors together because anti-cyclic
citrullinated peptide antibodies alone are only moderately sensitive, and the combination of the two markers improves diagnostic
accuracy, especially in the case of early rheumatoid arthritis. Furthermore, different rheumatoid factor isotypes alone or in
combination can be helpful when managing rheumatoid arthritis patients, from the time of diagnosis until deciding on the choice
of therapeutic strategy.

1. Introduction The aim of this review is to describe the clinical applica-

tions of testing for RFs.
Rheumatoid factors (RFs), a class of immunoglobulins (Igs)
that have different isotypes and affinities, were first detected
more than 70 years ago, but there is still much to discover
about the mechanisms underlying their production, physio- 2. Methods of Detection
logical role, and pathological effects [1]. Classic agglutination techniques were initially used because
Waaler described an antibody directed against serum of the ability of IgMs to induce agglutination. The first RF
gamma-globulins that promoted the agglutination of sheep detection assay was based on the fact that RF agglutinates
red blood cells sensitised by subagglutinating doses of rabbit sheep red blood cells sensitised with rabbit IgGs (i.e., the
antibodies in 1940 [2], although it had actually been pre- classic Waaler-Rose test) [2, 3], and this was followed by the
viously found in patients with liver cirrhosis and chronic development of other IgG carriers such as bentonite [5, 6] and
bronchitis by Kurt Meyer in 1922. In 1948, Rose described latex particles [7, 8].
these antibodies in patients with rheumatoid arthritis (RA) Automated techniques such as nephelometry and enzy-
[3], and in 1952 they were finally christened RFs because of me-linked immunosorbent assays gradually replaced the
their association with RA [4]. other semiquantitative methods because of their simplicity
However, although they owe their name to their first and greater reproducibility [9–12].
detection in RA patients, RFs are found in patients with Multiplexed immunoassaying is an emerging high-
other autoimmune and nonautoimmune diseases, as well as- throughput technique for the quantitative detection of mul-
in healthy subjects. tiple analytes from a single biological sample [13]. Although
728 Disease Markers

they have yet to be standardised and validated, multiplexed Table 1: Rheumatoid factor frequency in different diseases and
immunoassays can reduce analytical time and enhance accu- conditions.
racy. However, it is known that RFs can interfere with a Disease Frequency, %
number of laboratory immunoassays and lead to false positive
results: for example, in patients with high RF levels, the Arthritis
analysis of vancomycin can be compromised if serum rather Rheumatoid arthritis 70–90
than plasma samples are used [14, 15]. Juvenile idiopahtic arthritis 5
RFs can also interfere with other laboratory tests, includ- Psoriatic arthritis <15
ing those designed to detect anticardiolipin antibodies (espe- Reactive arthritis <5
cially if IgM levels are in the low positive range) [16], anti-
Other connective tissue diseases
𝛽2GPI antibodies [17], anti-HCV antibodies [18], antirubella
antibodies [19], thyroid assays [20, 21], and tests for carbohy- ̈
Primary Sjogren’s syndrome 75–95
drate antigen 19–9 [22] and various cytokines [23]. Mixed connective tissue disease 50–60
Systemic lupus erythematosus 15–35
Systemic sclerosis 20–30
3. Rheumatoid Factors in
Dermato-/polymyositis 20
Nonrheumatic Conditions
Systemic vasculitides (panarteritis 5–20
As shown in Table 1, RFs can be detected in patients with nodosa, Wegener’s granulomatosis)
many nonrheumatic conditions. Infections and chronic dis- Infectious diseases
eases may be characterised by the presence of serum RFs, Bacterial infections
but unlike those detected in RA patients, the RFs produced Subacute bacterial endocarditis 40
during infections are usually transient and not detrimental.
Chlamydia pneumoniae infection
Given the ability of RFs to increase the clearance of immune
complexes and the fact that RF-producing B cells may behave Klebsiella pneumoniae infection
as antigen-presenting cells (APCs) and aid the immune Syphilis primary-tertiary 8–37
response against the infectious antigens, it is likely that the Tuberculosis 15
net impact of RF production during infections is protective Viral infections
for the host [24, 26]. Coxsackie B virus infection 15
These natural RFs are generally low-affinity, polyreactive
Dengue virus infection 10
IgM antibodies produced by CD5-positive B cells [27, 28],
and coexistence of RF-positive B cells and nonautoimmune EBV and CMV infections 20
IgG antigen in healthy subjects suggests the existence of Hepatitis A, B and C virus infection 25
tolerance mechanisms [26]. HCV infection 40–76
RFs can be found in 40–50% of patients with HCV Herpes virus infection 10–15
infection, but their frequency can reach 76% [29]. Their HIV infection 10–20
production is probably due to chronic stimulation of the
Measles 8–15
immune system by HCV, and, as HCV infection is highly
prevalent in various countries (1.5–3% in southern Europe) Parvovirus infection 10
and represents the first cause of increased serum RFs, HCV Rubella 15
antibodies should be sought in all subjects with increased RF Parasitic
levels [29, 30] (Figure 1). Chagas 15–25
Malaria 15–18
4. RFs in Healthy Subjects Onchocerciasis 10
Toxoplasmosis 10–12
RF positivity has also been reported in the healthy population
Other diseases
[31–33], and up to 4% of young Caucasians may be RF
positive, with a similar distribution between the two genders. Mixed cryoglobulinemia type II 100∗
It is thought that genetic and environmental factors are Liver cirrhosis 25
responsible for the worldwide variability in distribution of Primary biliary cirrhosis 45–70
RFs: for example, their highest prevalence (up to 30%) has
Malignancy 5–25
been observed in North American Indians tribes [34–36]. The
RFs found in healthy subjects are different from those present After multiple immunisations 10–15
in RA patients as their titres are low/moderate and they Chronic sarcoidosis 5–30
are likely to be produced by CD5-expressing B cells as low- Healthy 50-year olds 5
affinity, poly-reactive IgMs without any signs of maturation Healthy 70-year olds 10–25
affinity [31]. The transient production of low-affinity IgM ∗
Monoclonal IgM rheumatoid factors; CMV: cytomegalovirus; EBV:
RFs may be induced by polyclonal B cell activators such as Epstein-Barr virus; HCV: hepatitis C virus; HIV: human immunodeficiency
bacterial lipopolysaccharides and Epstein-Barr virus [28, 37], virus. Adapted from [24, 25].
Disease Markers 729

RF positivity

Signs or symptoms of
persistent arthritis (60)

Yes No

Test for ACPA Titre

Positive Negative High Low

Consider conditions
RA very likely RA likely Test for ACPA other than RA
(see Table 1)

Positive Negative
Negative

Suspect pre-onset Screen for HCV

RA infection

Positive

Consult hepatologist

Figure 1: Proposed decision-making algorithm for patients who are rheumatoid factor positive at the first evaluation. RF: rheumatoid factor;
RA: rheumatoid arthritis; ACPA: anti-cyclic citrullinated protein/peptide antibody.

but it has been shown that high RF titres in healthy subjects detected in patients with type II mixed cryoglobulinemia and,
predict the development of RA [38]. Furthermore, IgM RFs to a lesser extent, in SS patients with lymphoproliferative
are sometimes observed in healthy elderly people, which disorders [24, 34].
suggests that they may be a consequence of the age-related
immune deregulation (Figure 1) [39, 40].
6. RFs and Rheumatoid Arthritis
5. RFs in Patients with Autoimmune Diseases Although RFs can be detected in patients with other connec-
tive tissue diseases, RF isotypes are helpful in the manage-
RFs are frequently detected in patients with systemic autoim- ment of RA patients from the time of diagnosis until deciding
mune diseases, such as systemic lupus erythematosus, mixed on the choice of therapeutic strategy (Figures 1 and 2) [44, 45].
connective tissue disease, polymyositis, and dermatomyositis RF testing in RA patients has a sensitivity of 60% to 90% and
(Table 1) [24, 25]. a specificity of 85% [46, 47].
Patients with Sjogren’s syndrome (SS) [41] and those with A number of hypotheses have been postulated in order
type II and III mixed cryoglobulinemia (usually HCV related) to explain the possible key role of RFs in RA, including their
[42] have the highest RF titres. capacity to increase the elimination of immune complexes
About 60% of the patients with primary SS are RF by macrophages [48], the improved cytotoxicity of antiviral
positive, with males having higher IgA RF levels than females antibodies [49], and the increased elimination of parasites [1].
[41]. It is also thought that the disease-related transformation It has also been suggested that RFs potentiate the presentation
of activated RF-positive B cell clones is involved in the patho- of antigens to T cells by means of the dendritic cell uptake of
genesis of the lymphoproliferative disorders that develop in immune complexes with exogenous antigens and by means of
about 5% of SS patients [43]. Most SS patients have high RF B cells, which seem to be more efficient APCs than other
titres of polyclonal RFs, whereas monoclonal RFs can be B cells [50] (Figure 3). Finally, it is possible that the rapid
730 Disease Markers

Help in diagnosis T cell-dependent Ag T cell-indipendent Ag

BCR
MHC II
MHC II
M𝜙 T B
Predict RA onset TCR
CD40 CD40L
Provide information
about prognosis

RF-PCs

Identify subgroups RF-PCs

of patients
Predict drug IgM-RF
response

Figure 2: Role of rheumatoid factors in the management of

rheumatoid arthritis patients.
IC Self-IgG

secretion of large amounts of low-affinity RFs prevents the

activation of higher-affinity RF B cells and additional B cells
[51–53]. Fc𝛾R Increased IC phagocytosis
Defining RFs as anti-IgG or anti-gamma-globulins is M𝜙 More efficient complement fixation
inaccurate because it restricts RF reactivity to the IgG Fc More efficient Ag presentation
IC Neutrophil attraction and activation
fragment. IgM RFs are the most frequently detected isotype,
but IgG, IgA, IgE, and IgD RFs can also be observed [54].
It has been shown that three RF isotypes (IgM, IgA, and
IgG) are detected in up to 52% of RA patients but in fewer
than 5% of patients with other connective tissue diseases.
Increased inflammation
Moreover, the presence of IgA and IgG RF isotypes in absence
of IgM-RF is more prevalent in patients with connective Figure 3: The immunological role of rheumatoid factors (RFs)
tissue diseases than in RA patients, whereas an increase in rheumatoid arthritis. RFs may be produced both in a T cell-
in both IgM and IgA RFs is almost exclusively observed dependent or T cell-independent pathway. Macrophages and B cells
in patients with RA [55, 56]. IgM-RF specificity increases may act as antigen-presenting cells and efficiently present antigens
considerably at high titres [57]. to T cells. Ag: antigen; BCR: B cell receptor; TCR: T cell receptor;
RF-PCs: rheumatoid factor plasma cells; IC: immune complex.

6.1. The Role of RFs in the Diagnosis of Rheumatoid Arthritis.

It has long been recognised that RFs play a pivotal role in
the differential diagnosis of polyarthritis because they make ACPA cut-off value should be ≥40 U/mL, which leads to a
it possible to identify RA patients [58]. For this reason, RF positive likelihood ratio of 5.49 and a negative likelihood ratio
testing has been one of the classification criteria for RA since of 0.50 [46, 67].
1987 [59] and, although many years have passed since their It has also been shown that RFs are useful in predicting
identification, their crucial role in classifying RA has been the development of RA, as the detection of IgM, IgA, and IgG
confirmed by the updated criteria [60]. RFs may predate its onset by years [38, 68], and it has been
However, in order to increase the specificity of the reported that their appearance in serum is sequential before
latest RA classification criteria, anti-cyclic citrullinated pro- diagnosis: first IgM RF, then IgA RF, and finally IgG RF [57,
tein/peptide antibody (ACPA) testing has been added. A 69].
meta-analysis [46] has shown that the pooled sensitivities
of ACPA and RF are similar, but ACPA positivity is more 6.2. Prognostic and Therapeutic Relevance in Rheumatoid
specific for RA than IgM RF, IgG RF, or IgA RF positivity Arthritis. The detection of IgM RFs is also helpful as a prog-
[61] and more specific for early RA than IgM RF [62]. On the nostic index, and some studies have shown that immunosup-
other hand, sensitivity is reduced because positivity for both pressive treatment can decrease serum RF levels. However,
ACPA and RF is a more stringent criterion than positivity the clinical usefulness of RFs in monitoring disease activity
for either alone [46]; combining ACPA and RF positivity is [70] and treatment response is limited [71].
more permissive in terms of sensitivity because the antibodies It has been shown that a progressive decrease in the RF
complement each other, especially for early RA [63–66]. levels parallels the decrease of clinical activity in patients
Furthermore, although the cut-off value of each commer- treated with traditional disease modifying antirheumatic
cial kit is slightly different, it has been suggested that the best drugs [72] or biologic agents such as infliximab [73–75],
Disease Markers 731

etanercept [76], adalimumab [77], rituximab [78, 79], and [9] K. Ailus, L. Melamies, T. Tuomi, T. Palosuo, and K. Aho,
abatacept or tocilizumab [80, 81]. “Measuring rheumatoid factor in nonrheumatoid subjects:
There are conflicting published data concerning the immunoturbidimetric assay, latex slide test, and enzyme-linked
potential role of RFs in predicting responses to antitumor immunosorbent assay compared,” Clinical Chemistry, vol. 37,
necrosis factor alpha (TNF-𝛼): some studies have found no. 10, part 1, pp. 1766–1769, 1991.
that RF positivity before therapy is insufficient to predict a [10] F. Wolfe, M. A. Cathey, and F. K. Roberts, “The latex test
response [82–85], whereas others have found that it predicts revisited: rheumatoid factor testing in 8,287 rheumatic disease
patients,” Arthritis and Rheumatism, vol. 34, no. 8, pp. 951–960,
a negative response [86, 87]. In particular, it has been reported
1991.
that high pretreatment levels of IgA RF are associated with a
[11] J. G. Larkin, R. D. Sturrock, and W. H. Stimson, “A rapid enzyme
poor clinical response to TNF-𝛼 inhibitors [88].
immunoassay for the detection of IgM rheumatoid factor. A
High serum levels of RF are predictors of more severe comparison of ’sero-negative’ and ’sero-positive’ rheumatoid
disease forms and B cell-depleting therapy can have a ben- patients,” Journal of Clinical and Laboratory Immunology, vol.
eficial effect: RF-positive RA patients have a better response 20, no. 4, pp. 207–209, 1986.
to rituximab than those who are RF negative [89–92]. [12] E. Ulvestad, L. L. Wilfred, and E. K. Kristoffersen, “Mea-
surement of IgM rheumatoid factor by ELISA,” Scandinavian
Journal of Rheumatology, vol. 30, no. 6, pp. 366–366, 2001.
7. Conclusions
[13] I. Abreu, P. Laroche, A. Bastos et al., “Multiplexed immunoassay
It has been demonstrated that low-affinity RFs appear to for detection of rheumatoid factors by FIDISTM technology,”
be key player in immune responses to many infectious Annals of the New York Academy of Sciences, vol. 1050, pp. 357–
organisms, and high-affinity RFs indicate more severe and 363, 2005.
persistent disease in patients with RA. RFs are probably the [14] D. F. LeGatt, G. B. Blakney, T. N. Higgins et al., “The effect
result of the immune response to inflammation (depending of paraproteins and rheumatoid factor on four commercial
immunoassays for vancomycin: implications for laboratorians
on genetic background) and may have regulatory effects on
and other health care professionals,” Therapeutic Drug Monitor-
Ig production by controlling B cell activation. ing, vol. 34, no. 3, pp. 306–311, 2012.
[15] G. M. Surnamebartels and G. Surnameribel-Madsen, “Cytokine
References measurements and possible interference from heterophilic
antibodies—Problems and solutions experienced with rheuma-
[1] T. Dörner, K. Egerer, E. Feist, and G. R. Burmester, “Rheumatoid toid factor,” Methods, vol. 61, no. 1, pp. 18–22, 2013.
factor revisited,” Current Opinion in Rheumatology, vol. 16, no. [16] S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International
3, pp. 246–253, 2004. consensus statement on an update of the classification criteria
[2] E. Waaler, “On the occurrence of a factor in human serum for definite antiphospholipid syndrome (APS),” Journal of
activating the specific agglutination of sheep blood corpuscles,” Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006.
Acta Pathologica Microbiologica Scandinavica, vol. 17, no. 2, pp. [17] G. Lakos, “Interference in antiphospholipid antibody assays,”
172–188, 1940. Seminars in Thrombosis and Hemostasis, vol. 38, no. 4, pp. 353–
[3] H. M. Rose, C. Ragan et al., “Differential agglutination of 359, 2012.
normal and sensitized sheep erythrocytes by sera of patients [18] D. L. Stevenson, A. G. Harris, K. R. Neal, and W. L. Irving,
with rheumatoid arthritis,” Proceedings of the Society for Exper- “The presence of rheumatoid factor in sera from anti-HCV
imental Biology and Medicine, vol. 68, no. 1, pp. 1–6, 1948. positive blood donors interferes with the detection of HCV-
specific IgM,” Journal of Hepatology, vol. 25, no. 5, pp. 621–626,
[4] R. M. Pike, S. E. Sulkin, and H. C. Coggeshall, “Serological reac-
1996.
tions in rheumatoid arthritis; factors affecting the agglutination
of sensitized sheep erythrocytes in rheumatid-arthritis serum,” [19] O. H. Meurman and B. R. Ziola, “IgM-class rheumatoid factor
Journal of Immunology, vol. 63, no. 4, pp. 441–446, 1949. interference in the solid-phase radioimmunoassay of rubella-
specific IgM antibodies,” Journal of Clinical Pathology, vol. 31,
[5] J. Ball, K. J. Bloch, T. A. Burch, J. H. Kellgren, J. S. Lawrence, no. 5, pp. 483–487, 1978.
and V. Tsigalidou, “Comparative studies of serologic tests
[20] N. Després and A. M. Grant, “Antibody interference in thyroid
for rheumatoid disease. II. A comparison of the bentonite
assays: a potential for clinical misinformation,” Clinical Chem-
flocculation test and the sensitized sheep cell agglutination test,”
istry, vol. 44, no. 3, pp. 440–454, 1998.
Arthritis and Rheumatism, vol. 5, pp. 61–69, 1962.
[21] A. M. Ramos-Levi, M. C. Montanez, I. Ortega, M. J. Cobo,
[6] J. Ball, R. De Graaff, H. A. Valkenburg, and F. W. Boerma, and A. L. Calle-Pascual, “A case of biochemical assay discrep-
“Comparative studies of serologic tests for rheumatoid disease. ancy: interference with measurement of thyroid-stimulating
I. A comparison of a latex test and two erythrocyte agglutination hormone due to rheumatoid factor,” Endocrinologı́a y Nutrición,
tests in a random population sample,” Arthritis and Rheuma- vol. 60, no. 6, pp. 342–345, 2013.
tism, vol. 5, no. 1, pp. 55–60, 1962.
[22] M. Berth, E. Bosmans, J. Everaert et al., “Rheumatoid factor
[7] C. M. Plotz and J. M. Singer, “The latex fixation test. I. interference in the determination of carbohydrate antigen 19-
Application to the serologic diagnosis of rheumatoid arthritis,” 9 (CA 19-9),” Clinical Chemistry and Laboratory Medicine, vol.
The American Journal of Medicine, vol. 21, no. 6, pp. 888–892, 44, no. 9, pp. 1137–1139, 2006.
1956. [23] E. Bartels, I. Falbe, E. Andersen, B. Danneskiold-Samsøe, H.
[8] C. M. Plotz and J. M. Singer, “The latex fixation test. II. Results Bliddal, and S. Ribel-Madsen, “Rheumatoid factor and its inter-
in rheumatoid arthritis,” The American Journal of Medicine, vol. ference with cytokine measurements: problems and solutions,”
21, no. 6, pp. 893–896, 1956. Arthritis, vol. 2011, Article ID 741071, 7 pages, 2011.
732 Disease Markers

[24] M. M. Newkirk, “Rheumatoid factors: host resistance or [40] J. Ursum, W. H. Bos, R. J. Van de Stadt, B. A. C. Dijkmans, and
autoimmunity?” Clinical Immunology, vol. 104, no. 1, pp. 1–13, D. Van Schaardenburg, “Different properties of ACPA and IgM-
2002. RF derived from a large dataset: further evidence of two distinct
[25] R. H. Shmerling and T. L. Delbanco, “The rheumatoid factor: an autoantibody systems,” Arthritis Research and Therapy, vol. 11,
analysis of clinical utility,” American Journal of Medicine, vol. 91, no. 3, article R75, 2009.
no. 5, pp. 528–534, 1991. [41] C. Dı́az-López, C. Geli, H. Corominas et al., “Are there clinical
[26] O. M. R. Westwood, P. N. Nelson, and F. C. Hay, “Rheumatoid or serological differences between male and female patients
factors: what’s new?” Rheumatology, vol. 45, no. 4, pp. 379–385, with primary Sjögren’s syndrome?” Journal of Rheumatology,
2006. vol. 31, no. 7, pp. 1352–1355, 2004.
[27] D. W. Dresser and A. M. Popham, “Induction of an IgM anti [42] D. Sansonno, G. Lauletta, L. Nisi et al., “Non-enveloped
(bovine) IgG response in mice by bacterial lipopolysaccharide,” HCV core protein as constitutive antigen of cold-precipitable
Nature, vol. 264, no. 5586, pp. 552–554, 1976. immune complexes in type II mixed cryoglobulinaemia,” Clin-
ical and Experimental Immunology, vol. 133, no. 2, pp. 275–282,
[28] L. Slaughter, D. A. Carson, and F. C. Jensen, “In vitro effects of 2003.
Epstein-Barr virus on peripheral blood mononuclear cells from
patients with rheumatoid arthritis and normal subjects,” Journal [43] Y. Masaki and S. Sugai, “Lymphoproliferative disorders in
of Experimental Medicine, vol. 148, no. 5, pp. 1429–1434, 1978. Sjögren’s syndrome,” Autoimmunity Reviews, vol. 3, no. 3, pp.
175–182, 2004.
[29] C. Palazzi, D. Buskila, S. D’Angelo, E. D’Amico, and I. Olivieri,
[44] W. Swedler, J. Wallman, C. J. Froelich, and M. Teodorescu,
“Autoantibodies in patients with chronic hepatitis C virus
“Routine measurement of IgM, IgG, and IgA rheumatoid
infection: pitfalls for the diagnosis of rheumatic diseases,”
factors: high sensitivity, specificity, and predictive value for
Autoimmunity Reviews, vol. 11, no. 9, pp. 659–663, 2011.
rheumatoid arthritis,” Journal of Rheumatology, vol. 24, no. 6,
[30] E. D. Charles, M. I. Orloff, E. Nishiuchi, S. Marukian, C. pp. 1037–1044, 1997.
M. Rice, and L. B. Dustin, “Somatic hypermutations confer
[45] D. Aletaha, F. Alasti, and J. S. Smolen, “Rheumatoid factor deter-
rheumatoid factor activity in hepatitis C virus-associated mixed
mines structural progression of rheumatoid arthritis dependent
cryoglobulinemia,” Arthritis and Rheumatism, vol. 65, no. 9, pp.
and independent of disease activity,” Annals of the Rheumatic
243–240, 2013.
Diseases, vol. 72, no. 6, pp. 875–880, 2013.
[31] M. Børretzen, C. Chapman, J. B. Natvig, and K. M. Thompson, [46] K. Nishimura, D. Sugiyama, Y. Kogata et al., “Meta-analysis:
“Differences in mutational patterns between rheumatoid factors diagnostic accuracy of anti-cyclic citrullinated peptide antibody
in health and disease are related to variable heavy chain family and rheumatoid factor for rheumatoid arthritis,” Annals of
and germ-line gene usage,” European Journal of Immunology, Internal Medicine, vol. 146, no. 11, pp. 797–808, 2007.
vol. 27, no. 3, pp. 735–741, 1997.
[47] V. P. K. Nell, K. P. Machold, T. A. Stamm et al., “Autoantibody
[32] J. F. Simard and M. Holmqvist, “Rheumatoid factor positivity in profiling as early diagnostic and prognostic tool for rheumatoid
the general population,” British Medical Journal, vol. 345, article arthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 12, pp.
e5841, 2012. 1731–1736, 2005.
[33] T. Tasliyurt, B. Kisacik, S. U. Kaya et al., “The frequency of [48] N. J. Zvaifler, “The immunopathology of joint inflammation in
antibodies against cyclic citrullinated peptides and rheumatoid rheumatoid arthritis,” Advances in Immunology, vol. 16, no. C,
factor in healthy population: a field study of rheumatoid pp. 265–336, 1973.
arthritis from northern turkey,” Rheumatology International,
[49] A. M. Haberman, J. William, C. Euler, and M. J. Shlomchik,
vol. 33, no. 4, pp. 939–942, 2013.
“Rheumatoid factors in health and disease: structure, function,
[34] M. M. Newkirk, “Rheumatoid factors: what do they tell us?” induction and regulation,” Current Directions in Autoimmunity,
Journal of Rheumatology, vol. 29, no. 10, pp. 2034–2040, 2002. vol. 6, pp. 169–195, 2003.
[35] L. T. H. Jacobsson, W. C. Knowler, S. Pillemer et al., “Rheuma- [50] J. J. Stewart, H. Agosto, S. Litwin et al., “A solution to the
toid arthritis and mortality. A longitudinal study in Pima rheumatoid factor paradox: pathologic rheumatoid factors can
Indians,” Arthritis and Rheumatism, vol. 36, no. 8, pp. 1045–1053, be tolerized by competition with natural rheumatoid factors,”
1993. Journal of Immunology, vol. 159, no. 4, pp. 1728–1738, 1997.
[36] T. Korpilähde, M. Heliövaara, O. Kaipiainen-Seppänen, P. [51] D. M. Lee, D. S. Friend, M. F. Gurish, C. Benoist, D. Mathis, and
Knekt, and K. Aho, “Regional differences in Finland in the M. B. Brenner, “Mast cells: a cellular link between autoantibod-
prevalence of rheumatoid factor in the presence and absence ies and inflammatory arthritis,” Science, vol. 297, no. 5587, pp.
of arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 4, pp. 1689–1692, 2002.
353–355, 2003. [52] R. A. Sweet, J. L. Cullen, and M. J. Shlomchik, “Rheumatoid
[37] D. W. Dresser, “Most IgM-producing cells in the mouse secrete factor B cell memory leads to rapid, switched antibody-forming
auto-antibodies (rheumatoid factor),” Nature, vol. 274, no. 5670, cell responses,” Journal of Immunology, vol. 190, no. 5, pp. 1974–
pp. 480–483, 1978. 1981, 2013.
[38] S. F. Nielsen, S. E. Bojesen, P. Schnohr, and B. G. Nordestgaard, [53] S. E. Burastero, P. Casali, R. L. Wilder, and A. L. Notkins,
“Elevated rheumatoid factor and long term risk of rheumatoid “Monoreactive high affinity and polyreactive low affinity
arthritis: a prospective cohort study,” Britich Medical Journal, rheumatoid factors are produced by CD5+ B cells from patients
vol. 345, article e5244, 2012. with rheumatoid arthritis,” Journal of Experimental Medicine,
[39] D. Van Schaardenburg, A. M. Lagaay, F. C. Breedveld, W. vol. 168, no. 6, pp. 1979–1992, 1988.
Hijmans, and J. P. Vandenbroucke, “Rheumatoid arthritis in a [54] H. W. Schroeder Jr. and L. Cavacini, “Structure and function of
population of persons aged 85 years and over,” British Journal of immunoglobulins,” Journal of Allergy and Clinical Immunology,
Rheumatology, vol. 32, no. 2, pp. 104–109, 1993. vol. 125, no. 2, pp. S41–S52, 2010.
Disease Markers 733

[55] T. Jónsson, K. Steinsson, H. Jónsson, Á. J. Geirsson, J. [70] T. Tillmann, R. Krishnadas, J. Cavanagh, and K. Petrides,
Thorsteinsson, and H. Valdimarsson, “Combined elevation of “Possible rheumatoid arthritis subtypes in terms of rheumatoid
IgM and IgA rheumatoid factor has high diagnostic specificity factor, depression, diagnostic delay and emotional expression:
for rheumatoid arthritis,” Rheumatology International, vol. 18, an exploratory case-control study,” Arthritis Research and Ther-
no. 3, pp. 119–122, 1998. apy, vol. 15, no. 2, article R45, 2013.
[56] T. Jónsson and H. Valdimarsson, “What about IgA rheumatoid [71] L. Barra, V. Bykerk, J. E. Pope et al., “Anticitrullinated protein
factor in rheumatoid arthritis?” Annals of the Rheumatic Dis- antibodies and rheumatoid factor fluctuate in early inflamma-
eases, vol. 57, no. 1, pp. 63–64, 1998. tory arthritis and do not predict clinical outcomes,” Journal of
[57] K. D. Deane, C. I. O’Donnell, W. Hueber et al., “The number of Rheumatology, vol. 40, no. 8, pp. 1259–1267, 2013.
elevated cytokines and chemokines in preclinical seropositive [72] T. R. Mikuls, J. R. O’Dell, J. A. Stoner et al., “Association of
rheumatoid arthritis predicts time to diagnosis in an age- rheumatoid arthritis treatment response and disease duration
dependent manner,” Arthritis and Rheumatism, vol. 62, no. 11, with declines in serum levels of IgM rheumatoid factor and anti-
pp. 3161–3172, 2010. cyclic citrullinated peptide antibody,” Arthritis and Rheuma-
[58] A. Miller, K. R. Mahtani, M. A. Waterfield, A. Timms, S. A. tism, vol. 50, no. 12, pp. 3776–3782, 2004.
Misbah, and R. A. Luqmani, “Is rheumatoid factor useful in [73] F. Bobbio-Pallavicini, C. Alpini, R. Caporali, S. Avalle, S.
primary care? A retrospective cross-sectional study,” Clinical Bugatti, and C. Montecucco, “Autoantibody profile in rheuma-
Rheumatology, vol. 32, no. 7, pp. 1089–1093, 2013. toid arthritis during long-term infliximab treatment,” Arthritis
[59] F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American research & therapy, vol. 6, no. 3, pp. R264–272, 2004.
Rheumatism Association 1987 revised criteria for the classifica- [74] L. De Rycke, X. Verhelst, E. Kruithof et al., “Rheumatoid
tion of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, factor, but not anti-cyclic citrullinated peptide antibodies, is
no. 3, pp. 315–324, 1988. modulated by infliximab treatment in rheumatoid arthritis,”
[60] D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 299–302,
arthritis classification criteria: an American College of Rheuma- 2005.
tology/European League Against Rheumatism collaborative [75] P. Caramaschi, D. Biasi, E. Tonolli et al., “Antibodies against
initiative,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569– cyclic citrullinated peptides in patients affected by rheumatoid
2581, 2010. arthritis before and after infliximab treatment,” Rheumatology
[61] S. Bas, S. Genevay, O. Meyer, and C. Gabay, “Anti-cyclic International, vol. 26, no. 1, pp. 58–62, 2005.
citrullinated peptide antibodies, IgM and IgA rheumatoid [76] H. A. Chen, K. C. Lin, C. H. Chen et al., “The effect of etanercept
factors in the diagnosis and prognosis of rheumatoid arthritis,” on anti-cyclic citrullinated peptide antibodies and rheumatoid
Rheumatology, vol. 42, no. 5, pp. 677–680, 2003. factor in patients with rheumatoid arthritis,” Annals of the
[62] S. Rantapää-Dahlqvist, B. A. W. De Jong, E. Berglin et al., “Anti- Rheumatic Diseases, vol. 65, no. 1, pp. 35–39, 2006.
bodies against cyclic citrullinated peptide and IgA rheumatoid [77] F. Atzeni, P. Sarzi-Puttini, D. Dell’ Acqua et al., “Adalimumab
factor predict the development of rheumatoid arthritis,” Arthri- clinical efficacy is associated with rheumatoid factor and anti-
tis and Rheumatism, vol. 48, no. 10, pp. 2741–2749, 2003. cyclic citrullinated peptide antibody titer reduction: a one-year
[63] B. E. Gilliam and T. L. Moore, “The role of anti-cyclic prospective study,” Arthritis Research & Therapy, vol. 8, no. 1,
citrullinated peptide (CCP) antibodies in early detection of article R3, 2006.
rheumatoid arthritis: an overview of the INOVA Diagnostics, [78] G. Cambridge, M. J. Leandro, J. C. W. Edwards et al., “Sero-
Inc. QUANTA Lite CCP assays,” Expert Opinion on Medical logic changes following B lymphocyte depletion therapy for
Diagnostics, vol. 6, no. 4, pp. 359–369, 2012. rheumatoid arthritis,” Arthritis and Rheumatism, vol. 48, no. 8,
[64] D. Manivelavan and C. K. Vijayasamundeeswari, “Anti-cyclic pp. 2146–2154, 2003.
citrullinated peptide antibody: an early diagnostic and prognos- [79] S. B. Cohen, P. Emery, M. W. Greenwald et al., “Rituximab for
tic biomarker of rheumatoid arthritis,” Journal of Clinical and rheumatoid arthritis refractory to anti-tumor necrosis factor
Diagnostic Research, vol. 6, no. 8, pp. 1393–1396, 2012. therapy: results of a multicenter, randomized, double-blind,
[65] C. Peoples, R. Valiyil, R. B. Davis, and R. H. Shmerling, “Clinical placebo-controlled, phase III trial evaluating primary efficacy
use of anti-cyclic citrullinated Peptide antibody testing,” Journal and safety at twenty-four weeks,” Arthritis and Rheumatism, vol.
of Clinical Rheumatology, vol. 19, no. 6, pp. 351–352, 2013. 54, no. 9, pp. 2793–2806, 2006.
[66] M. K. Demoruelle, M. C. Parish, L. A. Derber et al., “Anti-cyclic [80] R. J. Maneiro, E. Salgado, L. Carmona, and J. J. Gomez-Reino,
citrullinated peptide assays differ in subjects at elevated risk “Rheumatoid factor as predictor of response to abatacept,
for rheumatoid arthritis and subjects with established disease,” rituximab and tocilizumab in rheumatoid arthritis: systematic
Arthritis and Rheumatism, vol. 65, no. 9, pp. 2243–2252, 2013. review and meta-analysis,” Seminars in Arthritis and Rheuma-
[67] F. Debaugnies, G. Servais, V. Badot, D. Noubouossie, D. tism, vol. 43, no. 1, pp. 9–17, 2013.
Willems, and F. Corazza, “Anti-cyclic citrullinated peptide [81] C. Faillace and J. F. de Carvalho, “Rheumatoid factor appearance
antibodies: a comparison of different assays for the diagnosis after tocilizumab treatment seems to predict bad therapeutical
of rheumatoid arthritis,” Scandinavian Journal of Rheumatology, response in rheumatoid arthritis,” Rheumatology International,
vol. 42, no. 2, pp. 108–114, 2013. pp. 1909–1910, 2013.
[68] S. Rantapää-Dahlqvist, “What happens before the onset of [82] K. L. Hyrich, K. D. Watson, A. J. Silman, and D. P. M. Symmons,
rheumatoid arthritis?” Current Opinion in Rheumatology, vol. “Predictors of response to anti-TNF-𝛼 therapy among patients
21, no. 3, pp. 272–278, 2009. with rheumatoid arthritis: results from the British Society for
[69] K. D. Deane, J. M. Norris, and V. M. Holers, “Preclinical Rheumatology Biologics Register,” Rheumatology, vol. 45, no.
rheumatoid arthritis: identification, evaluation, and future 12, pp. 1558–1565, 2006.
directions for investigation,” Rheumatic Disease Clinics of North [83] W. H. Bos, G. M. Bartelds, G. J. Wolbink et al., “Differential
America, vol. 36, no. 2, pp. 213–241, 2010. response of the rheumatoid factor and anticitrullinated protein
734 Disease Markers

antibodies during adalimumab treatment in patients with

rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 10,
pp. 1972–1977, 2008.
[84] E. Salgado, J. R. Maneiro, L. Carmona, and J. Gomez-Reino, “nd
response to TNF antagonists in rheumatoid arthritis: systematic
review and meta-analysis of observational studies,” Joint Bone
Spine, 2013.
[85] E. Salgado, J. R. Maneiro, L. Carmona, and J. J. Gomez-
Reino, “Safety profile of protein kinase inhibitors in rheumatoid
arthritis: systematic review and meta-analysis,” Annals of the
Rheumatic Diseases, 2013.
[86] R. Klaasen, T. Cantaert, C. A. Wijbrandts et al., “The value of
rheumatoid factor and anti-citrullinated protein antibodies as
predictors of response to infliximab in rheumatoid arthritis: an
exploratory study,” Rheumatology, vol. 50, no. 8, pp. 1487–1493,
2011.
[87] C. Potter, K. L. Hyrich, A. Tracey et al., “Association of rheuma-
toid factor and anti-cyclic citrullinated peptide positivity, but
not carriage of shared epitope or PTPN22 susceptibility vari-
ants, with anti-tumour necrosis factor response in rheumatoid
arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 1, pp.
69–74, 2009.
[88] F. Bobbio-Pallavicini, R. Caporali, C. Alpini, R. Moratti, and
C. Montecucco, “Predictive value of antibodies to citrulli-
nated peptides and rheumatoid factors in anti-TNF-𝛼 treated
patients,” Annals of the New York Academy of Sciences, vol. 1109,
pp. 287–295, 2007.
[89] J. C. W. Edwards, L. Szczepański, J. Szechiński et al., “Efficacy
of B-cell-targeted therapy with rituximab in patients with
rheumatoid arthritis,” The New England Journal of Medicine, vol.
350, no. 25, pp. 2572–2581, 2004.
[90] L. Quartuccio, M. Fabris, S. Salvin et al., “Rheumatoid factor
positivity rather than anti-CCP positivity, a lower disability and
a lower number of anti-TNF agents failed are associated with
response to rituximab in rheumatoid arthritis,” Rheumatology,
vol. 48, no. 12, pp. 1557–1559, 2009.
[91] J. D. Isaacs, S. B. Cohen, P. Emery et al., “Effect of base-
line rheumatoid factor and anticitrullinated peptide antibody
serotype on rituximab clinical response: a meta-analysis,”
Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 329–336,
2013.
[92] J. D. Jones, I. Shyu, M. M. Newkirk, and W. F. Rigby, “A
rheumatoid factor paradox: inhibition of rituximab effector
function,” Arthritis Research and Therapy, vol. 15, no. 1, article
R20, 2013.